Century Therapeutics, Inc. $IPSC Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) by 32.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 906,827 shares of the company’s stock after selling 442,373 shares during the period. Renaissance Technologies LLC owned 0.50% of Century Therapeutics worth $2,049,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Prudential Financial Inc. acquired a new position in Century Therapeutics during the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp acquired a new stake in shares of Century Therapeutics in the first quarter valued at approximately $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics during the second quarter valued at approximately $38,000. Quadrant Private Wealth Management LLC raised its holdings in shares of Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after buying an additional 4,736 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Century Therapeutics during the second quarter worth approximately $51,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Stock Down 1.0%

Shares of IPSC stock opened at $1.98 on Tuesday. The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $2.23. Century Therapeutics, Inc. has a fifty-two week low of $0.44 and a fifty-two week high of $3.04. The stock has a market capitalization of $357.09 million, a P/E ratio of -1.74 and a beta of 1.57.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. On average, sell-side analysts anticipate that Century Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. HC Wainwright boosted their price target on Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Mizuho started coverage on shares of Century Therapeutics in a report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Century Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.